Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE
Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in the treatment of systemic lupus erythematosus (SLE) ... Read More
Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818
Chinese pharma company Kangpu Biopharmaceuticals said that it has wrapped up the first-in-human phase 1 clinical trial of CRL4-CRBN modulator KPG-818 in the US. KPG-818 ... Read More